Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if ANVS is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
6 top institutions tracked
Sentiment: unknown
No recent insider trades detected.
Red flags: 3
61 filers reported a long position in ANVS for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Empery Asset Management, LP | $4.5M | 2.4M | New |
| MARSHALL WACE, LLP | $3.4M | 1.8M | +55.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.1M | 1.6M | +88.8% |
| TUDOR INVESTMENT CORP ET AL | $2.5M | 1.4M | New |
| RENAISSANCE TECHNOLOGIES LLC | $1.9M | 1M | +188.3% |
| TWO SIGMA INVESTMENTS, LP | $1.1M | 579.6K | -7.7% |
| GEODE CAPITAL MANAGEMENT, LLC | $528.1K | 283.8K | +14.7% |
| BlackRock, Inc. | $464.7K | 249.9K | +79.1% |
| CITADEL ADVISORS LLC | $453.2K | 243.7K | New |
| VANGUARD FIDUCIARY TRUST CO | $330.2K | 177.5K | +34.4% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.